Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19

PURPOSE: Dexamethasone is the only drug that has consistently reduced mortality in patients with COVID-19, especially in patients needing oxygen or invasive mechanical ventilation. However, there is a growing concern about the relation of dexamethasone with the unprecedented rates of ICU-acquired re...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes, Luis Felipe, Rodriguez, Alejandro, Bastidas, Alirio, Parra-Tanoux, Daniela, Fuentes, Yuli V., García-Gallo, Esteban, Moreno, Gerard, Ospina-Tascon, Gustavo, Hernandez, Glenn, Silva, Edwin, Díaz, Ana Maria, Jibaja, Manuel, Vera, Magdalena, Díaz, Emilio, Bodí, María, Solé-Violán, Jordi, Ferrer, Ricard, Albaya-Moreno, Antonio, Socias, Lorenzo, Estella, Ángel, Loza-Vazquez, Ana, Jorge-García, Ruth, Sancho, Isabel, Martin-Loeches, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863516/
https://www.ncbi.nlm.nih.gov/pubmed/35217370
http://dx.doi.org/10.1016/j.jcrc.2022.154014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863516/
https://www.ncbi.nlm.nih.gov/pubmed/35217370
http://dx.doi.org/10.1016/j.jcrc.2022.154014

Ejemplares similares